Xilio Therapeutics, Inc. (XLO) stock
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)
Close on Nov 17, 2026Market cap $43.60MP/E –Yield –
Earnings
Xilio Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 22, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$10.00M
-47.6% on a year earlier
EPS, Q3 FY2026
-$0.30
-$0.11 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Xilio Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 22, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 10, 2026before the open | $10.00M | -47.6% | -$0.30 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 12, 2026before the open | $18.70M | +130.9% | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026before the open | $12.60M | +334.5% | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 23, 2026before the open | $13.70M | +705.9% | $0.81 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 13, 2025before the open | $19.10M | +730.4% | -$0.11 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 14, 2025before the open | $8.10M | +237.5% | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025before the open | $2.90M | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 11, 2025before the open | $1.70M | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024before the open | $2.30M | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | $2.40M | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 14, 2024before the open | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Apr 1, 2024after the close | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023after the close | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023before the open | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023before the open | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 2, 2023after the close | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 9, 2022before the open | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022before the open | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022before the open | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 1, 2022before the open | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Dec 2, 2021before the open | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Xilio Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Xilio Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Xilio Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Unlocking the Potential of Immuno-Oncology Therapies March 9, 2026 © 2026 Xilio Therapeutics, Inc. ®Update
- Update
- Results
- Results
- Update
- Update
- News
- Results
- Update
- Update
- Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, inUpdate
See a number that looks wrong?